Publications related to MS sherpa
Van Oirschot et al. (2021)
Title: A Two-Minute Walking Test With a Smartphone App for Persons With Multiple Sclerosis: Validation Study. JMIR Publications, Vol 5, No 11, doi: 10.2196/29128 PMID: 34787581
Cloosterman at al. (2021)
Title: The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa. Brain Sciences, volume 11, issue 10, 10.3390/brainsci11101305
Wester et al. (2021)
Title: Early HTA on the value of a decision support AI application in multiple sclerosis (in Dutch).
Lam et al. (2021)
Title: Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis, Multiple Sclerosis Journal, 10.1177/13524585211018103
Lam et al. (2020)
Title: Reliability, concurrent and ecological validity of smartphone-based cognition and walking tests (poster presentation ECTRIMS 2020)
Van Oirschot et al. (2020)
Title: Symbol Digit Modalities Test variant in a smartphone app for persons with multiple sclerosis: validation study. Journal of Medical Internet Research, mHealth & uHealth, 2020;8(10):e18160
Wendrich et al. (2019)
Title: Toward Digital Self-monitoring of Multiple Sclerosis: Investigating First Experiences, Needs, and Wishes of People with MS. International Journal of MS Care, 21(6):282-291
DOT MS Study
Can we safely discontinue first-line medication in MS patients with long-term absence of inflammation, without the return of inflammatory disease activity clinically and radiologically?
Is it possible to detect and predict (return of) inflammatory disease activity and disease progression with digital biomarkers using mobile applications such as MS sherpa?
(Amsterdam UMC) N= 130 patients.
Protocol approved by METC, started: Jun20
APPS MS study
Develop and explore measuring methods using built-in sensors of conventional smartphones and wearables to quantify fatigue, disease activity and progression in a day-to-day setting in patients with MS.
N= 125, 100 persons with MS, 25 healthy controls, collaboration with Amsterdam UMC, last patient visited in February 2021.
In data analysis phase, scientific publications are in preparation.
MS Self study
The aim of this study is to assess the validity, sensitivity and ease of use of new mobile self-monitoring tools for people with Relapsing-Remitting Multiple Sclerosis.
N= 25 MS patients, N= 79 healthy controls.
In this study, the primary aim is to evaluate the effectiveness, in terms of self-efficacy control and quality of life, and the cost-effectiveness of self-monitoring based management of MS through the use of the MS sherpa app compared to care as usual without MS sherpa.
N= 225, 125 intervention group, 100 control group, collaboration with Amsterdam UMC, 3 STZ hospitals, MS4Research institute and the Radboud University.